Gabapentin Enacarbil Market Trends, Demand & Growth by 2034

Coverage: By Type (Capsule, Tablet); Application (Post-Herpetic Neuralgia (PHN), Restless Legs Syndrome (RLS), Others) , and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034

Status : Data Released
Report Code : TIPRE00018109

Category : Life Sciences
No. of Pages : 150

Available Report Formats :
Last update date : April 17, 2026

Also Available in :

Korean German Japanese French Chinese Italian Spanish

Gabapentin Enacarbil Market Trends, Demand & Growth by 2034

Report Date: April 17, 2026 | Report Code: TIPRE00018109 Email: sales@theinsightpartners.com

Analysis Strategic Insights Market Drivers Regional Insights Report Scope Recent Developments FAQs

2025 Market Size

US$ 1.33 Bn

Base year value

2034 Forecast

US$ 2.67 Bn

Projected by 2034

CAGR 2026-2034

8.02 %

Growth rate

Addressable Market

US$ 17.96 Bn

(2026-2034)

The global gabapentin enacarbil market size is projected to reach US$ 2.67 billion by 2034 from US$ 1.33 billion in 2025. The market is anticipated to register a CAGR of 8.02% during the forecast period 2026-2034.

The Gabapentin Enacarbil Market Report is segmented by type into Capsule and Tablet. The application segment includes Post-Herpetic Neuralgia and Restless Legs Syndrome. The market evaluation is presented in US$ for the above segmental analysis. The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.

Market Research Highlights

Global market for Gabapentin Enacarbil was valued at US$ 1.33 Billion in 2025
Annual market size is expected to reach US$ 2.67 Billion by 2034
Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 17.96 Billion
Market is anticipated to register a CAGR of 8.02% during the forecast period
The United States represents a key market, supported by Prevalence of Neurological Disorders, Aging Population, Growing Awareness and Research, as well as evolving industry dynamics
Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
Market opportunities such as Emerging Markets, Cost-Effective Generics, Collaboration between Pharma Companies and Healthcare Centers are expected to influence market dynamics and addressable market
Report profiles industry participants, including GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Glenmark Pharmaceuticals Limited, Astellas Pharma Inc., AstraZeneca plc, Aurobindo Pharma., Takeda Pharmaceutical Company Limited, Intas Pharmaceuticals Ltd., while analyzing competitive strategies and innovation developments
Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

● Segmentations
● Geography
● Competitive Analysis
● Language Preferences

Gabapentin Enacarbil Market: Strategic Insights

Get Top Key Market Trends of this report.
This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Purpose of the Report

The report Gabapentin Enacarbil Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Gabapentin Enacarbil Market Segmentation Type

Capsule
Tablet

Application

Post-Herpetic Neuralgia
Restless Legs Syndrome

Gabapentin Enacarbil Market Report Scope

Report Attribute	Details
Market size in 2025	US$ 1.33 Billion
Market Size by 2034	US$ 2.67 Billion
Global CAGR (2026 - 2034)	8.02%
Historical Data	2021-2024
Forecast period	2026-2034
Segments Covered	By Type Capsule Tablet By Application Post-Herpetic Neuralgia Restless Legs Syndrome
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	GlaxoSmithKline plc Sun Pharmaceutical Industries Ltd. Novartis AG Pfizer Inc. Glenmark Pharmaceuticals Limited Astellas Pharma Inc. AstraZeneca plc Aurobindo Pharma. Takeda Pharmaceutical Company Limited Intas Pharmaceuticals Ltd.

Gabapentin Enacarbil Market Players Density: Understanding Its Impact on Business Dynamics

The Gabapentin Enacarbil Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Gabapentin Enacarbil Market Growth Drivers

Prevalence of Neurological Disorders: The increasing prevalence of neurological conditions like epilepsy, neuropathic pain, and restless leg syndrome is driving the demand for gabapentin enacarbil as an effective treatment.
Aging Population: The rising global aging population is contributing to a higher incidence of neurological disorders, further boosting the demand for gabapentin enacarbil.
Growing Awareness and Research: Increasing awareness of gabapentin enacarbil's efficacy and ongoing research to explore new applications and formulations are expected to drive market growth.

Frequently Asked Questions

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

The leading players of the market are: GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Novartis AG Pfizer Inc., Glenmark Pharmaceuticals Limited, Astellas Pharma Inc., AstraZeneca plc, Aurobindo Pharma., Takeda Pharmaceutical Company Limited, Intas Pharmaceuticals Ltd.

ThereÂ isÂ significantÂ promise inÂ the Gabapentin Enacarbil market,Â asÂ theÂ trendsÂ emergingÂ are multifarious.Â Innovative formulations and delivery systemsÂ thatÂ improveÂ patient compliance and,Â thus,Â treatment efficacyÂ areÂ crucialÂ developmentsÂ in this field.Â MoreÂ studiesÂ onÂ gabapentinÂ enacarbil are being conducted, opening doors toÂ new applications ofÂ thisÂ medicationÂ forÂ neurological disordersÂ suchÂ asÂ migraine and fibromyalgia.Â ThisÂ will further increaseÂ theÂ emphasis on personalized medicine and pharmacogenomics,Â whichÂ may lead to more targeted and effective use of gabapentin enacarbil, optimizing treatment outcomes for individual patients.

Gabapentin Enacarbil Market is expected to grow at a CAGR of 8.01% from 2026 to 2034

TheÂ primary drivers for theÂ Gabapentin Enacarbil marketÂ areÂ theÂ increasingÂ prevalence of neurological disordersÂ suchÂ asÂ epilepsy, neuropathic pain, and restless leg syndrome. The aging population,Â combinedÂ withÂ growingÂ awarenessÂ ofÂ these conditions, isÂ drivingÂ demand for effective treatments.Â FurtherÂ research and development activitiesÂ focusedÂ onÂ new applications and formulations of gabapentin enacarbilÂ willÂ alsoÂ contributeÂ toÂ theÂ growthÂ of theÂ market.

About Author (Life Sciences Research Team)

Mrinal Kerhalkar

Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

What are the Gabapentin Enacarbil Market report deliverables?

Comprehensive Market Sizing and Forecast Analysis
Detailed Segmentation Analysis
In-Depth Market Dynamics Assessment

Regional and Country-Level Insights
Competitive Landscape and Company Benchmarking
Strategic Business Intelligence

Recent Reports

Testimonials

The Insight Partners' SCADA System Market report is comprehensive, with valuable insights on current trends and future forecasts. The team was highly professional, responsive, and supportive throughout. We are very satisfied and highly recommend their services.

RAN KEDEM Partner, Reali Technologies LTDs

I requested a report on a very specific software market and the team produced the report in a few days. The information was very relevant and well presented. I then requested some changes and additions to the report. The team was again very responsive and I got the final report in less than a week.

JEAN-HERVE JENN Chairman, Future Analytica

We worked with The Insight Partners for an important market study and forecast. They gave us clear insights into opportunities and risks, which helped shape our plans. Their research was easy to use and based on solid data. It helped us make smart, confident decisions. We highly recommend them.

PIYUSH NAGPAL Sr. Vice President, High Beam Global

The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

YUKIHIKO ADACHI CEO, Deep Blue, LLC.

This is the first time I have purchased a market report from The Insight Partners.While I was unsure at first, I visited their web site and felt more comfortable to take the risk and purchase a market report.I am completely satisfied with the quality of the report and customer service. I had several questions and comments with the initial report, but after a couple of dialogs over email with their analyst I believe I have a report that I can use as input to our strategic planning process.Thank you so much for taking the extra time and making this a positive experience.I will definitely recommend your service to others and you will be my first call when we need further market data.

JOHN SUZUKI President and Chief Executive Officer, Board Director, BK Technologies

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

DR CHIJIOKE ONYIA MANAGING DIRECTOR, PineCrest Healthcare Ltd.

Reason to Buy